Please assess the completion status of the following clinical trial:

Trial Title: Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically Confirmed Non Small Cell Lung Cancer.~* Locally advanced disease previously treated with combined therapy (chemotherapy and surgery with or without radiotherapy, or chemotherapy and radiotherapy).~* Chemotherapy with regimens containing cisplatin or carboplatin is mandatory~* Response to combined therapy~Exclusion Criteria:~* No previous treatment with ZD1839 or any other EGFR-targeted therapy~* No progressive disease after combined therapy for locally advanced NSCLC~* No presence of metastatic disease~* No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ~* Any unresolved chronic toxicity from previous anticancer therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).